Education
About Us
Working with TipRanks
Follow Us
Ensysce Biosciences (ENSC)
NASDAQ:ENSC
ENSC Stock Chart & Stats
$1.01
-$0.28(-3.41%)
At close: 4:00 PM EST
$1.01
-$0.28(-3.41%)
Day’s Range― - ―
52-Week Range$0.31 - $5.20
Previous CloseN/A
Volume52.20K
Average Volume (3M)89.63K
Market Cap
$1.96M
Enterprise Value-$31.58K
Total Cash (Recent Filing)$1.67M
Total Debt (Recent Filing)$364.07K
Price to Earnings (P/E)―
Beta1.92
Next Earnings
Mar 26, 2026EPS Estimate
-1.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.29
Shares Outstanding3,632,307
10 Day Avg. Volume106,568
30 Day Avg. Volume89,627
Financial Highlights & Ratios
PEG Ratio0.70
Price to Book (P/B)3.83
Price to Sales (P/S)2.73
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-0.02
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda0.02
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.05
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Prodrug-based Abuse-deterrent PlatformEnsysce's prodrug-focused R&D targets abuse-deterrent and overdose-protective opioid/CNS medicines, a structural market need amid opioid regulation. Proprietary formulation science can create durable differentiation versus generics, support regulatory exclusivity, and enable premium positioning for prescribers and payers.
Committed Financing For Phase 3 PF614The $4M close and up to $16M contingent funding materially extend runway for Phase 3 PF614, enabling a key clinical de-risking milestone. Secured investor funding signals continued external support and reduces near-term financing pressure, improving prospects for program progression and partner interest.
Governance And Incentive Structure StrengthenedShareholder approvals expanded equity-based compensation, elected directors, and ratified the auditor, strengthening governance and retention tools. A larger incentive pool helps attract/retain scarce biotech talent long-term, while governance continuity supports strategic execution through clinical development phases.
Bears Say
Heavy Cash BurnSustained negative operating and free cash flow (~-$7.1M TTM) signals dependence on external capital to fund operations and trials. Persistent cash burn heightens refinancing risk, may force dilutive financings, and limits the company's ability to sustain multi-year clinical programs without partner or investor support.
Declining Revenue And Deep LossesA ~39% TTM revenue decline combined with deeply negative margins (net margin ~-275%) indicates the business lacks commercial traction and is not covering costs. Over time, this erodes the equity base, constrains reinvestment in R&D, and raises the bar on future financing and partner negotiations.
Very Small Operating ScaleA seven-person headcount reflects limited internal capacity to run concurrent clinical, regulatory, and commercial activities. This structural constraint increases reliance on CROs, partners, and external hires, raising execution risk and program coordination costs as the company advances late-stage trials.
Ensysce Biosciences News
ENSC FAQ
What was Ensysce Biosciences’s price range in the past 12 months?
Ensysce Biosciences lowest stock price was $0.31 and its highest was $5.20 in the past 12 months.
What is Ensysce Biosciences’s market cap?
Ensysce Biosciences’s market cap is $1.96M.
When is Ensysce Biosciences’s upcoming earnings report date?
Ensysce Biosciences’s upcoming earnings report date is Mar 26, 2026 which is in 19 days.
How were Ensysce Biosciences’s earnings last quarter?
Ensysce Biosciences released its earnings results on Nov 14, 2025. The company reported -$1.29 earnings per share for the quarter, missing the consensus estimate of -$0.825 by -$0.465.
Is Ensysce Biosciences overvalued?
According to Wall Street analysts Ensysce Biosciences’s price is currently Overvalued.
Does Ensysce Biosciences pay dividends?
Ensysce Biosciences does not currently pay dividends.
What is Ensysce Biosciences’s EPS estimate?
Ensysce Biosciences’s EPS estimate is -1.26.
How many shares outstanding does Ensysce Biosciences have?
Ensysce Biosciences has 3,632,307 shares outstanding.
What happened to Ensysce Biosciences’s price movement after its last earnings report?
Ensysce Biosciences reported an EPS of -$1.29 in its last earnings report, missing expectations of -$0.825. Following the earnings report the stock price went down -4.854%.
Which hedge fund is a major shareholder of Ensysce Biosciences?
Currently, no hedge funds are holding shares in ENSC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ensysce Biosciences
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Technical Analysis
NovaBay Pharma
―
Galmed Pharmaceuticals
―
Cyclerion Therapeutics
―
Silo Pharma
―
Alzamend Neuro
―
Ownership Overview
―
Insiders
0.62% Mutual Funds
11.05% Other Institutional Investors
87.97% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---